Prescient Therapeutics Ltd (ASX: PTX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Prescient Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Prescient Therapeutics Ltd (ASX: PTX)
Latest News
Healthcare Shares
Guess which ASX biotech stock just rocketed 29% on big FDA news
PTX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Prescient Therapeutics Ltd
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
PTX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Nov 2024 | $0.04 | $0.00 | 0.00% | 175,293 | $0.04 | $0.04 | $0.04 |
31 Oct 2024 | $0.04 | $0.00 | 0.00% | 1,014,184 | $0.04 | $0.04 | $0.04 |
30 Oct 2024 | $0.05 | $0.00 | 0.00% | 179,630 | $0.05 | $0.05 | $0.04 |
29 Oct 2024 | $0.05 | $0.00 | 0.00% | 106,282 | $0.05 | $0.05 | $0.04 |
28 Oct 2024 | $0.05 | $0.00 | 0.00% | 218,783 | $0.04 | $0.05 | $0.04 |
25 Oct 2024 | $0.04 | $0.00 | 0.00% | 527,972 | $0.04 | $0.05 | $0.04 |
24 Oct 2024 | $0.04 | $0.00 | 0.00% | 306,000 | $0.04 | $0.04 | $0.04 |
23 Oct 2024 | $0.05 | $0.00 | 0.00% | 110,507 | $0.04 | $0.05 | $0.04 |
22 Oct 2024 | $0.05 | $0.00 | 0.00% | 7,600 | $0.05 | $0.05 | $0.05 |
21 Oct 2024 | $0.04 | $0.00 | 0.00% | 198,178 | $0.04 | $0.05 | $0.04 |
18 Oct 2024 | $0.04 | $0.00 | 0.00% | 75,000 | $0.04 | $0.04 | $0.04 |
17 Oct 2024 | $0.04 | $0.00 | 0.00% | 212,797 | $0.04 | $0.04 | $0.04 |
16 Oct 2024 | $0.04 | $0.00 | 0.00% | 600,000 | $0.04 | $0.04 | $0.04 |
15 Oct 2024 | $0.04 | $0.00 | 0.00% | 362,189 | $0.05 | $0.05 | $0.04 |
14 Oct 2024 | $0.04 | $0.00 | 0.00% | 398,672 | $0.05 | $0.05 | $0.04 |
11 Oct 2024 | $0.05 | $0.00 | 0.00% | 578,734 | $0.05 | $0.05 | $0.05 |
10 Oct 2024 | $0.05 | $0.00 | 0.00% | 515,110 | $0.05 | $0.05 | $0.05 |
09 Oct 2024 | $0.05 | $0.00 | 0.00% | 137,859 | $0.05 | $0.05 | $0.05 |
08 Oct 2024 | $0.05 | $0.00 | 0.00% | 448,405 | $0.05 | $0.05 | $0.05 |
07 Oct 2024 | $0.05 | $0.00 | 0.00% | 677,428 | $0.05 | $0.05 | $0.05 |
04 Oct 2024 | $0.05 | $0.00 | 0.00% | 810,467 | $0.05 | $0.05 | $0.04 |
03 Oct 2024 | $0.05 | $0.00 | 0.00% | 2,124,129 | $0.04 | $0.05 | $0.04 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
30 Sep 2024 | Gavin Shepherd | Buy | 235,908 | $9,435 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr James Campbell | Non-Executive Director | Nov 2014 |
Dr Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of Australian and international biotechnology companies. Dr Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited, where, as a member of the executive team he helped transform a research based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr Campbell sits on the Board of Australia's peak biotechnology body, AusBiotech. He is Chairman of Risk Committee.
|
Mr Steven Yatomi-Clarke | Chief Executive OfficerManaging Director | Nov 2014 |
Mr Yatomi-Clarke, at Prescient, manages a team in Australia and the US and has been in strategy development; licensing; initiating and managing clinical trials; identifying research directions and pre-clinical research design; fundraising and business development. He has over 17 years of experience in investment banking specialising in healthcare and biotechnology, where he involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies. He has also been a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy.
|
Mr Steven (Steve) Barnard Engle | Non-Executive ChairmanNon-Executive Director | Nov 2014 |
Mr Engle has executive leadership experience with public and private biotechnology companies developing breakthrough products in metabolic, autoimmune, oncologic and infectious disease areas. Most recently, Steve was the CEO of Gradalis, a biotechnology company focused on the development of personalized cellular immunotherapies to treat cancer, and which is preparing a clinical study for product registration in patients with ovarian cancer. Prior to that, he was the CEO of CohBar, a clinical-stage biotechnology company developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan. Previously, he served as Chairman and CEO of antibody therapeutics company XOMA, which developed antibody drug candidates for many of the major pharmaceutical companies, and of B-cell tolerance therapeutics company, La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance and developed the first B cell toleragen for lupus patients. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval of and to launch Nicotrol for smoking cessation. He is member of the board of New Zealand based Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a member of the board of the Lupus Foundation of America. Other current directorships include Author-It Software Company. Former directorships (last 3 years): Gradalis, CohBar (NASDAQ:CWBR). He is Member of Risk Committee.
|
Dr Allen James Ebens | Non-Executive Director | Jun 2020 |
Dr Ebens is Chief Science Officer at Vera Therapeutics, a San Francisco California based biotechnology company. Dr Ebens is a drug developer, having overseen the advancement of drug development projects from concept to clinical development including polatuzumab, which is approved by the US FDA and is now marketed for use in diffuse large B-cell lymphoma. Dr Ebens was an early recruit to Juno Therapeutics (Juno), which is recognised as a one of the first CAR T companies, and a leader in the clinical advancement of CAR-T cancer therapies. At Juno, Dr Ebens was in establishing the scientific capabilities of the company in the emerging field of CAR-T. Previously, Dr Ebens held executive positions at global pharma and biotechnology leaders Genentech and Exelixis, where he worked from concept to clinic across therapeutic platforms including targeted therapies, antibodies, antibody-drug conjugates, and T cell recruiting antibodies. He has also held roles in biotech companies including Bioseek and NGM Biopharmaceuticals.
|
Dr Ellen Gwen Feigal | Non-Executive Director | May 2023 |
Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Dr Feigal serves as a Board member for Xencor Inc (NASDAQ: XNCR) a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure (NASDAQ: NXTC) a clinical-stage biotechnology company developing new immunotherapies to treat cancer.
|
Dr Gavin James Shepherd | Non-Executive Director | Jul 2024 |
Dr Shepherd is a medical professional with 25 years of experience in medicine and a track record in in various consulting businesses. He completed his GAICD qualification in 2011 and is a nonexecutive director of Lateral Pharma Pty Ltd.
|
Ms Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary | Feb 2015 |
-
|
Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Mr David Kenley | 19,925,332 | 2.47% |
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 11,687,125 | 1.45% |
Dr Gavin James Shepherd & Mrs Catherine Shepherd <Tpj Superannuation Fund A/C> | 10,000,000 | 1.24% |
Mr Andrew Morrison Stewart | 9,233,176 | 1.15% |
Citicorp Nominees Pty Limited | 8,698,067 | 1.08% |
Mr Richard Thomas Hayward Daly & Mrs Sarah Kay Daly <The Daly Family Super A/C> | 7,000,000 | 0.87% |
HSBC Custody Nominees (Australia) Limited | 6,474,208 | 0.80% |
Gavncath Pty Ltd <Shepherd Investment A/C> | 6,150,000 | 0.76% |
Mr Clinton Craig Hopper | 6,093,595 | 0.76% |
BNP Paribas Noms Pty Ltd | 5,999,055 | 0.74% |
Mr Anthony Graeme Halls & Mrs Simone Justine Halls <Ellalily Superfund A/C> | 5,900,000 | 0.73% |
Boycecorp Pty Ltd <Boycecorp Discretionary A/C> | 5,809,400 | 0.72% |
Mr Steven Yatomi-Clarke | 5,790,647 | 0.72% |
Dr Rosamund Julian Banyard & Mr Phillip Stanley Holten <R Banyard Super Fund A/C> | 5,705,525 | 0.71% |
Mr David Kenley <Kenley Super Plan A/C> | 4,700,000 | 0.58% |
Dossman Pty Ltd | 4,682,077 | 0.58% |
Mr Jakov Kulis | 4,250,000 | 0.53% |
Netwealth Investments Limited <Super Services A/C> | 4,229,560 | 0.53% |
Dr Vincent William Fitzgerald & Mrs Penelope Fitzgerald <Fitzgerald Super Fund A/C> | 4,080,518 | 0.51% |
Sb Investments Pty Ltd <Broadley Unit A/C> | 3,333,928 | 0.41% |